Orsini Pharmacy

AUGUST 23, 2023

23, 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Regeneron Pharmaceuticals, Inc. Regeneron”) has chosen Orsini to be the exclusive specialty pharmacy partner for VEOPOZ TM (pozelimab-bbfg).

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

JUNE 8, 2023

Often when pharmacy benefit manager (PBM) agreements and specialty pharmacy agreements are put into place, no one considers the 1 or 2 percent of the overall population that is made up of rare disease patients. You have to have a plan for every drug as you want to provide patients with access to care as fast as possible.

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

JULY 11, 2023

Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that BioMarin Pharmaceutical has selected it to dispense ROCTAVIAN™ ( valoctocogene roxaparvovec-rvox ). ROCTAVIAN is the first gene therapy for the treatment of severe Hemophilia A.

Specialty Pharmacies 75

Specialty Pharmacies 75

Orsini Pharmacy

MAY 18, 2023

One of the initial steps in the RFP process is payor credentialing to see which specialty pharmacy can meet this goal. Many pharmacy benefit managers (PBMs) have some type of comprehensive credentialing process in place because rare diseases are complex with many drug nuances to manage.

Specialty Pharmacies 95

Specialty Pharmacies 95

Orsini Pharmacy

JANUARY 26, 2023

Almost 1 in 10 Americans are affected by a rare disease. 1 Common challenges rare disease patients face include limited treatment options, little to no research on the disease, difficulty finding experienced physicians to treat the rare condition, and difficulty obtaining an accurate diagnosis.

Specialty Pharmacies 52

Specialty Pharmacies Pharmaceutical Manufacturing 52

pharmaphorum

DECEMBER 21, 2021

There are currently an estimated 300 million people living with one or more Rare Diseases across the world. There are over 7,000 Rare Diseases that have been identified, yet only 5% have treatments. One factor is the lack of substantive data about Rare Diseases, which makes understanding specific diseases very difficult.

Drug Development 98

Drug Development Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

Pharmafile

FEBRUARY 28, 2023

Published date: 28/02/2023 Summary: Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring rare disease products to market. read more

Specialty Pharmacies 40

Specialty Pharmacies 40

FDA Law Blog: Biosimilars

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Drug Development 59

Drug Development 59

Orsini Pharmacy

FEBRUARY 9, 2023

According to the National Institutes of Health (NIH), approximately 7,000 rare diseases affect between 25 and 30 million Americans (almost 1 in 10) 1. In general, it is often difficult and time-consuming to diagnose a rare disease.

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

NOVEMBER 30, 2022

Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Provention Bio, Inc. as a specialty pharmacy for TZIELD ® (teplizumab).

Specialty Pharmacies 52

Specialty Pharmacies Diabetes 52

Express Pharma

OCTOBER 15, 2023

He will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease portfolio and also future forays into novel therapeutics. Zydus Lifesciences announced the appointment of Punit Patel as President and CEO, Americas.

Doctor of Pharmacy 101

Doctor of Pharmacy Vaccines 101

Drug Channels

FEBRUARY 6, 2024

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Specialty Pharmacies 40

Specialty Pharmacies Communication 40

assurecare

SEPTEMBER 8, 2022

What is Specialty Pharmacy? I have been a pharmacist for more than 25 years and since I started working within the specialty pharmacy arena in 2006, it has changed dramatically over the years. In 2006, not many people had previously heard of specialty pharmacy, although the practice has been around since the 1970s.

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

AUGUST 30, 2023

ELK GROVE VILLAGE, IL – August 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Darin DeCarlo has been named the company's first ever Chief Growth Officer.

Specialty Pharmacies 52

Specialty Pharmacies 52

Pharma Marketing Network

DECEMBER 12, 2023

Upcoming Informa Connect Events: Speaker Programs Summit – February 26-28, 2024 Event Name: Rare Disease Summit – March 19-21, 2024 PAP – Patient Assistance & Access Programs – March 19-21, 2024 Hub and Specialty Pharmacy Models East – March 19-21, 2024 Pharma Forum – March 24-27, 2024 Pharmaceutical Compliance Congress (..)

Specialty Pharmacies 40

Specialty Pharmacies 40

pharmaphorum

OCTOBER 26, 2022

But Giacomo Chiesi, head of Chiesi Global Rare Diseases, thinks of his 6,000-person company as a family business. For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Caring for a global community. “We

Pharmaceutical Manufacturing 96

Pharmaceutical Manufacturing 96

pharmaphorum

FEBRUARY 11, 2022

If consummated, the deal would bring in around €350 million for Ipsen , leaving the company as a specialty pharma pure-play in cancer, rare diseases and neuroscience and ending its strategy of adopting a combined prescription and over-the-counter (OTC) medicines business model. billion last year.

102

102

Orsini Pharmacy

JUNE 23, 2023

Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that Aimmune Therapeutics, a Nestle Health Science Company, has selected it as a limited distribution partner for VOWST™ (fecal microbiota spores, live-brpk) to prevent the recurrence of C.

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

OCTOBER 13, 2022

Dealing with a rare disease or complex condition can be exhausting, stressful, frustrating, costly, and at times, frightening. A dedicated specialty pharmacy partner can make an enormous difference in the journey by smoothing out road bumps, eliminating detours and wrong turns, and providing compassionate guidance all along the way.

Specialty Pharmacies 52

Specialty Pharmacies 52

Drug Channels

FEBRUARY 6, 2023

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and Rare Disease Innovation & Partnership Summit, three industry-leading access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships.

Specialty Pharmacies 55

Specialty Pharmacies Hospitals Drug Development 55

Orsini Pharmacy

DECEMBER 15, 2022

2 When choosing a specialty pharmacy to support patients with Tardive Dyskinesia , it's essential to consider a team experienced in rare diseases, ready to listen, provide counseling on treatment, help with side-effect management, and assist with sourcing third-party financial assistance.

Specialty Pharmacies 52

Specialty Pharmacies 52

Orsini Pharmacy

OCTOBER 27, 2022

Mucopolysaccharidosis (MPS) is an inherited metabolic disease in which the body does not produce enough enzymes to break down sugars into simpler molecules or produces enzymes that do not work correctly. As part of your MPS patient's treatment, Orsini Specialty Pharmacy provides the following:

Specialty Pharmacies 52

Specialty Pharmacies 52

European Pharmaceutical Review

MAY 24, 2023

Advanz Pharma, a UK headquartered global pharmaceutical company focusing on specialty and rare disease medicines in Europe, will be responsible for registration and commercialisation in Europe. Which biosimilar candidates will be part of the extended partnership?

Biosimilars 91

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 91

pharmaphorum

JANUARY 27, 2021

We’ve chosen to focus our first edition of the magazine on a topic close to our hearts, rare diseases. As our rare disease specialist agency Dudnyk says: “We are seeing a growing separation between healthcare professionals and patients. A patient’s account of living with a rare disease in the COVID-19 pandemic.

Communication 52

Communication Drug Development 52

pharmaphorum

APRIL 28, 2022

Rare diseases aren’t as rare as the appellation suggests. For instance, according to the US Government Accountability Office , 30 million Americans have a rare disease, a little less than 10% of the population. For pharmaceutical companies, rare diseases present many challenges. Novo’s name change.

Immunity 57

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 57

Pharmaceutical Business Review

MAY 25, 2023

It is also an important next step in Advanz’s ambition to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe.” Advanz Pharma CEO Steffen Wagner said: “This partnership positions Advanz Pharma as a key future player in European biosimilars. “It

Biosimilars 52

Biosimilars Hospitals 52

Pharma Marketing Network

DECEMBER 8, 2022

Hub and Specialty Pharmacy Models East – March 20-22, 2023. Rare Disease Innovation & Partnering Summit – March 21-23, 2023. Upcoming Informa Connect Events: Speaker Programs Summit – February 27-March 1, 2023. Pharma Forum – March 19-22, 2023.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

Safe Biologics

NOVEMBER 12, 2023

A 2021 ASBM multi-specialty physician survey (n=401) revealed the value of the interchangeable designation to prescribers specifically:57% said a biosimilar carrying an interchangeable designation would make them more likely to prescribe it. ASBM surveys of U.S.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Safe Biologics

DECEMBER 6, 2023

A 2021 ASBM multi-specialty physician survey (n=401) revealed the value of the interchangeable designation to prescribers specifically:57% said a biosimilar carrying an interchangeable designation would make them more likely to prescribe it. Considered rare, an estimated 8,000 people in the U.S. ASBM surveys of U.S. Read it here.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Drug Channels

NOVEMBER 13, 2020

Anndi also suffers from a rare disease and requires treatment with an orphan drug. Anndi’s story illustrates how a patient taking a specialty drug can lose out, even as others—her health plan, its PBM, and a sketchy intermediary—profit from a manufacturer’s patient support funds. Your kids have definitely heard her voice.

52

52

LifeProNow

MARCH 27, 2023

Patient needs, precision therapies to address disease complexity as well as advances in science and technology are evolving rapidly. Nubeqa has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease. EU, Japan, and China.

Bioethics 130

Bioethics Compounding Diabetes 130

Pharma Marketing Network

JUNE 9, 2021

Mamta Chhabra , Global Marketing Lead, Rare Disease, UCB. Claudia Smalley , Associate Director, Specialty Analytics, AbbVie. Karen Root , Director, Experience Strategy, Boehringer Ingelheim. Lars Merk , Senior Director, Global Commercial Digital Innovation, AstraZeneca.

52

52

Drug Channels

OCTOBER 17, 2022

Additional sessions include coverage on: Navigating regulatory reform in the trade & channel space Building forward-thinking commercialization and channel strategies for patient affordability Maximizing GTN impact Future of value-based agreements, measurement, contracting and pull through Innovative limited pharmacy networks The Drug Supply Chain (..)

Biosimilars 56

Biosimilars 56

Pharmaceutical Technology

MAY 30, 2023

Abiogen Pharma specialises in osteoarticular and bone metabolism diseases amongst other therapy areas. The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Hospitals Drug Development 52

pharmaphorum

SEPTEMBER 8, 2021

Joining Dominic Tyer for this instalment of Biotech Insight are Prithu Somani, senior manager of forecasting and business analytics at Genmab, and Kantar Health’s vice president of oncology and specialty therapeutics, Jay Grisolano.

52

52

pharmaphorum

JULY 16, 2021

French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for $28 million upfront. . Ipsen’s other main research areas are oncology and rare diseases.

89

89

pharmaphorum

JULY 15, 2021

It includes talent from award-winning agencies — Carling Communications, rare-disease specialty agency Dudnyk, 2e Creative, Blue Latitude Health, Healthcircle, as well as new acquisitions StoneArch and the Hive Health Group. ” “Lacey and I have a really close working relationship,” added Damien Parsonage.

Communication 52

Communication 52